<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="471">
  <stage>Registered</stage>
  <submitdate>8/09/2005</submitdate>
  <approvaldate>22/09/2005</approvaldate>
  <actrnumber>ACTRN12605000460606</actrnumber>
  <trial_identification>
    <studytitle>Phase II study of myeloablative allogeneic transplantation using pegylated G-CSF mobilised peripheral blood stem cells.</studytitle>
    <scientifictitle>A Phase I/II trial to evaluate the effects of allogeneic pegylated G-CSF mobilized stem cells in the treatment of haematological malignancy to inhibit the incidence of GVHD.</scientifictitle>
    <utrn />
    <trialacronym>BMT Neulasta</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Acute Graft Versus Host Disease following allogeneic peripheral blood stem cell transplant from am HLA identical sibling for a haematological malignancy.</healthcondition>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>All donors will receive 12mg of pegylated G-CSF as a single dose sub-cutaneously 4 days prior to stem cell collection.</interventions>
    <comparator />
    <control>Uncontrolled</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of grades II-IV acute GVHD</outcome>
      <timepoint>Day 100</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Donor endpoints:
Incidence and severity of adverse events. Number of days with restriction of regular activities. 
Total CD34+ and CD3+ yield.
Extended immunophenotyping of cellular content of peripheral blood stem cell product percentage + absolute CD3/4, CD3/8, CD4/25, CD13/33, CD16/56, CD5/19, DC subsets + CD11b/Gr-1 dim. </outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Recipient endpoints:
Engraftment: Time to ANC &gt;500/l (first of 3 consecutive days).
Time to platelet independence (first of 5 days unsupported &gt; 20x109/l). 
Chimerism studies:Day +28, Day +100 and +6 months
Treatment Response: Disease free survival and overall survival.
Chronic GVHD: Incidence of limited and extensive chronic GVHD. 
Organ involvement by chronic GVHD. Duration of treatment for chronic GVHD.
Immune reconstitution: Peripheral blood analysis pre-conditioning and Day +16, and months +1, +2, +3, +6, +12, +18,+24:T cell subsets (including T helper and cytotoxic subsets plus assessment of relative proportions of naiive and memory cells), B cells and NK cells. 3 colour FACS stains for CD3/4/8, CD5/19, CD16/56, CD4/25, CD3/45RA/45RO. 
Serum immunoglobulin levels monitored 3 monthly from Day 100 onward.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of haematological malignancy.Allogeneic peripheral blood stem cell transplant from an HLA identical sibling.Ablative conditioning regime (CY/TBI, BU/CY, FLU/MEL). ECOG performance status 0-2.Suitable HLA-identical sibling donor, fit for peripheral blood stem cell collection.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>19/01/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>47</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>A/Prof Geoff Hill</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Royal Brisbane and Women's Hospital</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Royal Brisbane and Women's Hospital.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Royal Melbourne Hospital.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Alfred Hospital.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor Geoff Hill</name>
      <address>The Queensland Institute of Medical Research
300 Herston Road
Brisbane QLD 4006</address>
      <phone>+61 7 38453763</phone>
      <fax />
      <email>geoffH@qimr.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Madonna Fuery</name>
      <address>Cancer Care Clinical Trials
Bone Marrow Transplantation (BMT) Department
Royal Brisbane and Women's Hospital
Level 5
Joyce Tweddell Building
Butterfield Street
Herston Brisbane QLD 4029</address>
      <phone>+61 7 36365750</phone>
      <fax />
      <email>Madonna_Fuery@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>